> ## Content Index
> Fetch the complete content index at: https://www.theamericanquorum.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Eli Lilly Cuts Insulin List Prices 70% and Expands $35 Monthly Cap as Pressure Builds Over U.S. Affordability
- URL: https://www.theamericanquorum.com/taq-historical-2023-03-04-healthcare/
- Published: 2023-03-05T04:59:00.000Z
- Updated: 2023-03-05T04:59:00.000Z
- Description: Eli Lilly said it will cut prices on major insulins by 70%, cap eligible patients’ out-of-pocket costs at $35 a month and price unbranded lispro at $25 a vial.
- Author: Kenneth R. Deans Jr.
- Tags: Healthcare, #Import 2026-08-31 22:59

Eli Lilly announced a sweeping reduction in U.S. insulin prices Wednesday, saying it will cut the list prices of its most widely prescribed insulins by **70%**, expand a program capping eligible patients’ out-of-pocket costs at $35 per month and reduce the price of its unbranded insulin lispro to $25 per vial beginning May 1.

The company’s [announcement](https://investor.lilly.com/news-releases/news-release-details/lilly-cuts-insulin-prices-70-and-caps-patient-insulin-out-pocket?ref=theamericanquorum.com) represents one of the most significant voluntary pricing changes by a major insulin manufacturer and comes amid years of pressure from patients, lawmakers and clinicians over the gap between insulin’s manufacturing history and the prices many Americans face at the pharmacy counter.

## Three pricing changes at once

Lilly said it will cut the list prices of Humalog and Humulin by 70% in the fourth quarter of 2023\. It will also reduce the list price of its unbranded insulin lispro injection to $25 per vial in May, which the company describes as the lowest list price for a mealtime insulin available in the United States. A newly launched basal insulin, Rezvoglar, is being offered at a list price 78% below Lantus, according to the company.

The third component is an expansion of Lilly’s Insulin Value Program. People with commercial insurance can use a savings card to limit out-of-pocket insulin expense to $35 a month, while uninsured patients can obtain a similar cap through the company’s program. Lilly said participating retail pharmacies would automatically cap out-of-pocket costs at $35 for people with commercial insurance using Lilly insulin.

A contemporaneous [Washington Post report](https://www.washingtonpost.com/business/2023/03/01/eli-lilly-insulin/?ref=theamericanquorum.com) noted that the move follows persistent political attention to insulin affordability and could put competitive pressure on Novo Nordisk and Sanofi, the other large manufacturers that dominate the U.S. insulin market.

## A federal $35 cap already changed Medicare

Lilly’s announcement comes just as a new federal policy is changing insulin costs for Medicare beneficiaries. The Inflation Reduction Act caps covered insulin cost sharing at $35 per month in Medicare. A federal [CMS fact sheet](https://www.cms.gov/newsroom/fact-sheets/inflation-reduction-act-lowers-health-care-costs-millions-americans?ref=theamericanquorum.com) describes the provision as one of the law’s immediate drug-cost protections, alongside broader changes that will phase in over several years.

The Medicare cap is important but does not automatically reach every person with diabetes. People with employer coverage, individual-market insurance or no insurance remain subject to different benefit designs and pricing arrangements. Lilly’s voluntary program is designed in part to close that gap for users of its products.

The federal government had previously tested a $35 insulin model through Medicare Part D. CMS’s [Part D Senior Savings Model](https://www.cms.gov/priorities/innovation/innovation-models/part-d-savings-model?ref=theamericanquorum.com) encouraged participating plans and manufacturers to offer predictable copayments for insulin. The Inflation Reduction Act now makes a monthly cap a statutory Medicare benefit rather than a voluntary demonstration.

## List price is only one layer of the insulin market

The announcement also highlights the complexity of U.S. drug pricing. Insulin’s list price is not necessarily what a health plan, pharmacy-benefit manager or patient ultimately pays. Manufacturers may provide rebates and discounts to intermediaries, while patients’ out-of-pocket expenses can depend on deductibles, coinsurance and whether a specific product is on a plan’s formulary.

That means a 70% list-price reduction can have different effects across the system. For an uninsured patient paying close to cash price, a lower list price can be immediately meaningful. For an insured patient with fixed copayments, the direct impact may be smaller. For health plans and pharmacy-benefit managers, a lower list price can change rebate economics and formulary negotiations.

A March 1 [Forbes report](https://www.forbes.com/sites/alexknapp/2023/03/01/eli-lilly-slashes-insulin-prices-up-to-70-and-expands-program-that-caps-out-of-pocket-cost-at-35/?ref=theamericanquorum.com) described the move as both a response to affordability concerns and a potential reset in a market where high list prices have become politically difficult to sustain. The central question now is whether competitors match Lilly’s reductions and whether the changes produce durable savings across insurance categories.

## Affordability pressure is moving from policy to market

CMS had already emphasized lower insulin costs in its 2023 Medicare enrollment communications. An agency [open-enrollment release](https://www.cms.gov/newsroom/press-releases/biden-harris-administration-kicks-medicare-open-enrollment-lower-premiums-improved-benefits-2023?ref=theamericanquorum.com) highlighted the $35 monthly insulin cap as a major new benefit for Medicare participants. The combination of federal law and manufacturer action suggests that insulin affordability is shifting from a long-running policy debate toward concrete changes in what patients may pay.

Yet the effects will not be uniform. Diabetes treatment varies substantially by product, dose and insurance status, and some patients use insulin from more than one manufacturer. Savings-card programs also have eligibility rules and can require patients to take specific enrollment steps. Clinicians and pharmacists will still need to help patients match prescriptions with the lowest-cost covered options.

The economic stakes are large because insulin is not discretionary. People with type 1 diabetes require insulin to live, and many people with type 2 diabetes depend on it for adequate glucose control. When costs become unaffordable, patients may ration doses, delay refills or make tradeoffs against food, housing and other necessities.

## A test for the rest of the industry

Lilly’s decision puts a clear number on the competitive challenge: 70% lower list prices for Humalog and Humulin, a $25 vial for unbranded lispro and a $35 monthly out-of-pocket ceiling for many users. Those commitments are more concrete than generalized pledges to improve access, and they give policymakers and patients benchmarks against which to judge other manufacturers.

The broader drug-pricing environment is also changing. The Inflation Reduction Act begins a series of Medicare reforms that include inflation rebates and future price negotiation for selected high-spending drugs. Although those provisions operate differently from Lilly’s voluntary insulin cuts, they add to the pressure on manufacturers to justify prices that have risen far faster than production costs.

The immediate result is that one of the country’s largest insulin producers has broken with the pricing structure that defined much of the past decade. Whether that becomes an industry-wide shift will depend on competitor responses, insurer behavior and the practical ability of patients to obtain the promised prices at the pharmacy counter.